Interstitial lung disease: Progress and problems

Postgraduate Medical Journal

Volumn 82, Issue 970, 2006, Pages 494-499

  Bourke, S J ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMIODARONE; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BLEOMYCIN; COLCHICINE; CORTICOSTEROID; GAMMA INTERFERON; INFLIXIMAB; PENICILLAMINE; PIRFENIDONE; PREDNISOLONE;

ALLERGIC PNEUMONITIS; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE DISEASE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; HISTIOCYTOSIS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG HEMOSIDEROSIS; LUNG INFILTRATE; LUNG LAVAGE; LUNG SARCOIDOSIS; PHYSICIAN; PNEUMOCONIOSIS; PNEUMONIA; REVIEW; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY; TUBEROUS SCLEROSIS; WEGENER GRANULOMATOSIS;

AGE OF ONSET; CONNECTIVE TISSUE DISEASES; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; PROGNOSIS;

EID: 33747497014     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2006.046417     Document Type: Review

References (55)

1. Cushley MJ, Davison AG, Dußois RM, et al. The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults: British Thoracic Society recommendations. Thorax, 1999;54(suppl 1).
2. King TE. Clinical advances in the diagnosis and therapy of interstitial lung diseases. Am J Respir Crit Care Med 2005;172:268-79.
3. DuBois TM, Costabel U. Diffuse lung disease: classification and diagnostic approach. In: Gibson GJ, Geddes DM, Costabel U, et al. Respiratory medicine. London: Elsevier Science, 2003:1545-56.
4. Johnson IDA, Prescott RJ, Chalmers JC, et al. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Thorax 1997;52:38-44.
5. Joint statement of the American Thoracic Society and European Respiratory Society, Idiopathic pulmonary fibrosis: diagnosis and treatment. Am J Respir Crit Care Med 2000;161:646-64.
6. American Thoracic Society/European Respiratory Society. International multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
7. Ward PA, Hunnlnghake GW. Lung inflammation and fibrosis. Am J Resp Crit Core Med 1998;157:s123-9.
8. Kennedy JI, Myers JL, Plumb VJ, et al. Amiodarone pulmonary toxicity: clinical, radiologic and pathologic correlations. Arch Intern Med 1987;147:50-5.
9. Flaherty KR, King TE, Raghu G, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med 2004;170:904-10.
10. McLoud T. Role of high-resolution computed tomography in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;172:408-9.
11. Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis. Am J Respir Crit Care 2005;172:488-93.
12. Drent M, Jacobs JA, Wagenaar SS. Bronchoalveolar lavage. Eur Respir Mon 2000;14:63-78.
13. Langford CA, Huffman GS. Wegener's granulomatosis. Thorax 1999;54:629-37.
14. Vasallo R, Ryu IH, Colby TV, et al. Pulmonary Langerhans cell histiocytosis. N Engl J Med 2000;342:1969-77.
15. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2002;166:215-35.
16. Fishbein M. To biopsy or not biopsy: assessing the role of surgical biopsy in the diagnosis of idiopathic pulmonary fibrosis. Chest 2005;128:s520-5.
17. Lacasse Y, Selman M, Costabel U, et al. Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med 2003;168:952-8.
18. Bourke SJ, Dolphin JC, Boyd G, et al. Hypersensitivity pneumonitis: current concepts. Eur Respir J 2001;18(suppl 32):81-92.
19. British Thoracic Society. Guidelines on diagnostic flexible bronchoscopy. Thorax 2001;56(suppl 1):1-21.
20. Lettieri CJ, Veerappan GR, Helman DL, et al. Outcomes and safety of surgical lung biopsy for interstitial lung disease. Chest 2005;127:1600-5.
21. Wells AU. Histopathological diagnosis in diffuse lung disease: an ailing gold standard. Am J Respir Crit Care Med 2004;170:828-9.
22. Hubbard R, Lewis S, Richards K, et al. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 1996;347:284-9.
23. Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid grastroesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006;27:136-42.
24. Steele MP, Speer MC, Loyd JE, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005;172:1146-52.
25. Selman M, Pardo A, Barrera L, et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med 2006;173:188-98.
26. Bouros D, Antoniou KM. Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J 2005;26:693-702.
27. Dermedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-42.
28. Myers JL, Veal CF, Shin MS, et al. Respiratory bronchioloitis causing interstitial lung disease: a clinicopathological study of six cases. Am Rev Respir Dis 1987;135:880-4.
29. Mavridou D, Laws D. Respiratory bronchiolitis associated interstitial lung disease (RB-ILD): a case of an acute presentation. Thorax 2004;59:910-11.
30. Swigris JJ, Berry GJ, Raffin TA, et al. Lymphoid interstitial pneumonia. Chest 2002;122:2150-64.
31. Bellomo R, Finlay M, McLaughlin P, et al. Clinical spectrum of cryptogenic organising pneumonitis. Thorax 1991;46:554-8.
32. Riha RL, Duhig EE, Clarke BE, et al. Survival of patients with biopsy-proven usual interstitial pneumonia and non-specific interstitial pneumonia. Eur Respir J 2002;19:1114-18.
33. Wells AU. Lung disease in association with connective tissue diseases. Fur Respir Mon 2000;14:137-64.
34. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis- associated interstitial lung disease. Am J Respir Crit Care Med 2001;164:1182-5.
35. Owens GR, Fallansbee WP. Cardiopulmonary manifestations of systemic sclerosis. Chest 1987;91:118-27.
36. Camus P, Gibson GJ. Iatrogenic respiratory disease. In: Gibson GJ, Geddes DM, Costabel U, et al. Respiratory medicine. London: Elsevier Science, 2003:764-806.
37. Adams PC, Gibson GJ, Morley AR, et al. Amiodarone pulmonary toxicity: clinical and subclinical features. Q J Med 1986;59:449-71.
38. White DA, Stover DE. Severe bleomycin-induced pneumonitis: clinical features and response to corticosteroids. Chest 1984;86:723-8.
39. British Thoracic Society. Recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-5.
40. Colombel JF, Loltus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004; 126:1-23.
41. Ostor AJ, Crisp AJ, Somerville MF, et al. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ 2004;329:1266-8.
42. Riegert-Johnson DL, Godfrey JA, Myers JL, et al. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflammatory Bowel Disease 2002;8:186-91.
43. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNF alpha blockers in adults with rheumatoid arthritis. Rheumatology 2005;44:157-63.
44. Bourke SJ, Boyd G. Pigeon fancier's lung. BMJ 1997;315:70-1.
45. Nemery B, Bast A, Behr J, et al. Interstitial lung disease induced by exogenous agents: factors governing susceptibility. Eur Respir J 2001;18(suppl 32):30-42.
46. Ohtani Y, Saiki S, Kitaichi M, et al. Chronic bird fancier's lung: histopathological and clinical correlation. An application of the 2002 ATS/ ERS consensus classification of the idiopathic interstitial pneumonias. Thorax 2005;60:665-71.
47. Perez-Padilla R, Salas J, Chapela R, et al. Mortality in Mexican patients with chronic pigeon breeder's lung compared with those with usual interstitial pneumonia. Am Rev Respir Dis 1993;148:49-53.
48. Bourke SJ, Anderson K, Lynch P, et al. Chronic simple bronchitis in pigeon fancier's. Chest 1989;95:598-601.
49. Bourke SJ, Carter R, Anderson K, et al. Obstructive airways disease in non-smoking subjects with pigeon fancier's lung. Clin Expt Allergy 1989;19:629-32.
50. Kokkarinen JI, Tukiainen HO, Terho EO. Effect of corticosteroid treatment on the recovery of pulmonary function in farmer's lung. Am Rev Respir Dis 1992;145:3-5.
51. American Thoracic Society. Statement on sarcoidosis. Am J Respir Crit Care Med 1999;160:736-55.
52. Martin WJ, Iannuzzi MC, Gail DB, et al. Future directions in sarcoidosis research. Am J Respir Crit Care Med 2004;170:567-71.
53. Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis-diagnosis and management. Q J Med 1999;91:103-17.
54. Ward K, O'Connor C, Odium C, et al. Prognostic value of bronchoalveolar lavage in sarcoidosis: the critical influence of disease presentation. Thorax 1989;44:6-12.
55. Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996;51:238-47.